Antibodies play an important role in therapy and investigative biomedical research. The TNF--family member Receptor Activator of NF--κB (RANK) is known for its role in bone homeostasis and is increasingly recognized as a central player in immune regulation and epithelial cell activation.
Introduction
RANK (Receptor activator of NF--κB) is a signaling receptor [3] engaged by its ligand RANKL [4] but blocked by OPG (osteoprotegerin) that binds RANKL and prevents it from recognizing RANK [5] (for review see [6] ). The RANK--RANKL--OPG triad was originally identified as a regulator of bone mass based on expression of the signaling receptor by pre--osteoclasts and their differentiation into mature osteoclasts by RANKL [5, 7, 8] . Thus, mice deficient for or overexpressing any of the three proteins display alterations in bone density. The triad is under the regulatory control by different factors, among which sex hormones that link osteoporosis with menopausal hormonal changes or hormone ablation therapy [9] . Hence, a treatment of osteoporosis consists of the administration of Denosumab, a human monoclonal RANKL--neutralizing antibody [10] . Similar reagents are used in animal models, such as anti--RANKL monoclonal antibody IK22--5 [2, 11] , RANK--Fc fusion protein [12, 13] or recombinant OPG [14] . A murine RANK--specific monoclonal antibody (R12--31) has been generated, which was reported as unable to block the binding of RANK--Fc to RANKL [2] . Recently, an antagonist RANK single--chain variable fragment (scFv) reactive against human and mouse RANK has been identified with a capacity to inhibit osteoclastogenesis [1] .
The role of RANK is not limited to bone. Macrophages and dendritic cells are of the same lineage as osteoclasts and express this receptor. RANK activation of these cells enhances the immune response by increased cell survival and cytokine production [3,4,8,15--20] . Also epithelial cells are responsive to RANKL. Thymic medullary epithelial cells require RANK activation signals for maturation [21--23] (for review see [24] ), the development of intestinal microfold epithelial cells is dependent on RANK signals [25, 26] , and RANK activation is required for the development of lactating mammary gland epithelial cells during pregnancy [27--29] (for review see [9] ). However, although studies employ RANK--specific antibodies [13, 25, 30, 31] , these antibodies remain insufficiently characterized.
Therefore, in addition to potential therapeutic applications, specific antibodies are important investigative tools to study the distribution and function of RANK, RANKL and OPG. The RANKL monoclonal antibody IK22--5 [2] was used to demonstrate the production of RANKL by osteocytes [32] , T cells [32--34] , innate lymphoid cells [35] or lymph node stromal cells [36] . The monoclonal antibody R12--31 has shown RANK expression in synovial tissue and the myeloid cell lineage [37--39] .
Although reported as non--antagonist [2] a rigorous analysis of its affinity and its biological activity against mouse and human RANK had not been published. Recently, a scFv reactive against RANK has been generated by phage display [1] . It was shown to recognize human RANK by ELISA, by immunoblot and by immunofluorescence on human osteoclasts and to inhibit osteoclastogenesis of the murine RAW cell line. A detailed affinity and functional analysis of the scFv to evaluate its utility in preclinical studies and investigative research was not performed.
In the present study, we generated an antibody (RANK--02) from the amino acid sequence of RANK--binding scFv and compared it with the anti--RANK monoclonal antibody R12--31 with regard to biological activity, interference with RANKL--RANK interaction, distinct or shared epitopes and recognition of primary RANK--expressing cells. We find that both mAbs recognize human and mouse RANK with high affinity but differ in their biological activity. Both mAbs were used to identify RANK--expressing primary cells and R12--31 was administered to mice to induce the differentiation of intestinal microfold cells.
Material and Methods

Production of RANK--02 antibody
The variable domains from the anti--RANK scFv [1] were cloned into human IgG1 heavy chain and light chain expression vectors. These were co--transfected into Chinese Hamster Ovary cells, and the IgG1, named RANK--01, was purified using MabSelect SuRe (GE Healthcare). RANK--01 demonstrated severe aggregation on production, correlating with the aggregation pattern seen originally with the anti--RANK scFv (see Lam M., Master's thesis, University of Alberta, 2011; https://era.library.ualberta.ca/public/view/item/uuid:0036405c--4d76--49a0--b2c7--21c148af44f4).
Analysis of the variable domain sequence identified the absence of a canonical heavy chain framework methionine residue at Kabat position 82. Site directed mutagenesis was therefore employed to insert the missing codon, generating a new human IgG heavy chain vector. This vector was co--transfected with the existing light chain vector to generate an improved anti--RANK IgG1, named RANK--02, which did not aggregate on production.
ELISA
For ELISA with RANK--02, recombinant human and mouse RANK--Fc were coated overnight at 20 µg/ml in PBS in 96 well plates (Nunc). Plates were washed with PBS, blocked for 1 h at room temperature with PBS containing 3% (w/v) milk powder and washed again. RANK--02 and an isotype control IgG1 were added, the plates incubated for one hour at room temperature and washed three times with PBS/0.1% Tween 20. Peroxidase--coupled goat anti--human kappa light chain antibody (Sigma, A7164) was diluted 1:5000, 50 µl was added to each well and the plates were incubated for 1 h. After three washes with PBS/0.1% Tween 20, 50 µl of tetramethylbenzidine (TMB, Sigma Aldrich) was added to each well and incubated for five minutes before neutralization with 50 µl 0.5 M H 2 SO 4 . Plates were read on a PerkinElmer Envision 2100 plate reader measuring absorbance at 450 nm and analyzed in GraphPad PRISM. For ELISA with R12--31, hRANK and mRANK--Fc were coated at 1 µg/ml in PBS for 3 h at 37°C. Plates were blocked with PBS containing 4 % (w/v) milk powder and 0.05 % Tween 20 for 1 h 37°C. Titrated amounts of R12--31 were added, the plates incubated for 1 h at 37°C and washed 3 times with PBS/0.05 % Tween 20. Peroxidase--coupled goat anti--rat IgG, light chain specific (Jackson Immunoreasearch) was diluted 1:5000, 100 µl was added to the plates and the plates were incubated for 1 h at 37°C. After three washes with PBS/0.05% Tween 20, 75µl of tetramethylbenzidine (TMB) was added to each wells and then neutralized with 25 µl HCL 1 N. Plates were read at 450 nm on Multiskan Ex (MTX Labsystems Inc.).
For the competitive ELISA assay, hRANK--Fc was coated at 5 µg/ml. After blocking, wells were incubated for 1 h at 37°C with titrated amounts of the four antibodies (RANK--02 hIgG1 anti--RANK, NIP288 hIgG1 control; R12.31 rat IgG2a anti--mRANK, rat IgG2a control). Without washing, a constant volume of conditioned supernatant of 293T cells transfected with Flag--ACRP--hRANKL (5 µl) or Flag--mRANKL (20 µl) was added to wells. Volumes were chosen for their abilities to generate a close to maximal but non--saturating signal. Binding of Flag--ACRP--hRANKL was revealed with biotin--conjugated M2--antibody (0.5µg/ml) (Sigma) and streptavidin--HRP (Jackson immunoresearch)
(1/4000). anti--CD14 (M5E2, BD--Pharmingen). Fixable Viability Dye eFluor® 780 (ebioscience) was used to exclude the dead cells. Flow cytometry was performed on a FACS--Calibur (BD) or Gallios (Beckman--Coulter, Fullerton, CA, USA) and the flow cytometry data were analyzed using the FlowJo software (Treestar, Ashland, OR, USA). Langerhans and dermal dendritic cells were isolated from human skin as described [40] .
Affinity measurements by surface plasmon resonance
To determine recognition of different epitopes, Jurkat JOM2 mRANK:Fas and Jurkat JOM2 hRANK:Fas were incubated on ice for 15 min with increasing amounts of unlabeled competitor antibody, followed without washing by a fixed concentration of biotinylated test mAb for 20 min on ice. Cells were then washed and binding of test mAb revealed with PE--conjugated streptavidin.
Cell culture
All cells were maintained in a humidified incubator with 5% CO 2 at 37°C. Jurkat JOM2, Jurkat JOM2 mRANK:Fas and Jurkat JOM2 hRANK:Fas, were grown in RPMI 1640 medium supplemented with 10 % FCS. Jurkat JOM2 mRANK:Fas and Jurkat JOM2 hRANK:Fas were generated according to a described protocol [41, 42] . HEK 293 cells stably transfected with mRANK [31] or with hRANK (a kind gift of Dr.
D.Heymann, University of Nantes, France) were grown in DMEM supplemented with 10 % FCS, gentamicin (10 µg/ml) and penicillin/streptomycin (100 U/ml). G418 selection (500 µg/ml) was used to maintain HEK 293--mRANK cell line. by ELISA according to the manufacturer's instructions (Immunodiagnostic systems).
Statistical analysis
Statistical significance was calculated by one or two way ANOVA/Bonferroni using the PRISM software. *<0.05, **<0.01, ***<0.001, ****<0.0001, ns= not statistically significant.
Results
Specificity and affinity of R12--31 and RANK--02 for mouse RANK
The nucleic acid sequence obtained from a human RANK--Fc--selected scFv [1] was modified to generate a recombinant human antibody, termed RANK--02 (see Material and Methods). We first investigated its affinity and specificity for mouse (m) RANK and could expect recognition of mRANK because the scFv inhibited osteoclast formation of a murine cell line. However, no further analyses were reported [1] . To first evaluate binding to mRANK we performed an ELISA in comparison with the known RANK--specific mAb R12--31 [2] . Both antibodies recognized the fusion protein in a dose dependent manner (Fig. 1A) . Affinities of both mAbs were determined by surface plasmon resonance, and they bound mRANK--Fc with high affinity (~0.2 nM) ( Table 1) . To further confirm their specificity, we performed flow cytometry analysis on two different cell lines both expressing the extracellular domain of mRANK and compared the signal intensity with that obtained with the parental cell lines. We used the Jurkat human T cell line, deficient for Fas (Jurkat JOM2) and stably expressing the mRANK extracellular domain fused to the transmembrane and intracellular domains of human Fas (Jurkat JOM2 mRANK:Fas) [41] , and the human embryonic kidney cells HEK 293 cells, stably transfected with full--length mRANK (HEK 293--mRANK). The antibodies failed to recognize parental cell lines but bound the mRANK--expressing cells (Fig. 1B) . The analysis of the mean fluorescence intensity showed that R12--31 generated a slightly stronger signal than RANK--02
( Supplementary Fig. 1A, B) . Therefore, RANK--02 and R12--31 specifically recognize the extracellular domain of mRANK with high affinity. Fig.2A ). Apoptosis was not observed in response to GST alone ( Supplementary Fig.2B ). Incubation of JOM2 mRANK:Fas cells with R12--31 led to cell death ( Fig. 2A) , while its isotype control (data not shown) and the RANK--02 antibody had no observed effect even at high concentrations (Fig. 2B) . These results suggest that R12--31 and RANK--02
antibodies have distinct biological properties. These findings were validated using a canonical NF--κB activation assay in HEK293 cells transfected with full--length mRANK. Stimulation of these cells with GST--mRANKL as a positive control or with R12--31 both induced NF--κB activation, while RANK--02 did not (Fig. 2C, D) . R12--31 and RANK--02 were used at 25 µg/ml and 50 µg/ml, respectively, to be in line with the concentrations of 100 nM of scFV used in Newa et al. and the expected low biological activity of the latter (Fig. 2B ) [1] . Because the RANK--02 equivalent scFv could inhibit osteoclastogenesis [1] , we next assayed the antagonist activity of RANK--02. Indeed, when Jurkat JOM2 mRANK:Fas cells were pre--incubated with 50 µg/ml RANK--02 prior to addition of recombinant mRANKL, cell death was almost completely inhibited (Fig.  2E) . Similarly, the anti--RANK--02 antibody diminished NF--κB activation by recombinant RANKL (Fig.  2F ), but again less efficiently than the anti--RANKL antibody IK22--5 ( Fig.  2E,  F) . Altogether, the above data demonstrate that R12--31 and RANK--02 bind mRANK with similar affinities, but differ in their biological effects.
Specificity and affinity of R12--31 and RANK--02 for human RANK
We extended these analyses to human (h) RANK and observed that RANK--02 and R12--31 also recognized hRANK--Fc in ELISA (Fig. 3A) . We next compared the affinity of both antibodies to hRANK-- (Fig. 3B) . Although R12--31 labelled hRANK--expressing cells by flow cytometry, it did so less efficiently than RANK--02, as its MFI values were lower compared to those obtained with RANK--02 ( Supplementary  Fig.  1C,  D) . This may be attributable to the lower affinity of R12--31 to hRANK. This confirms that the specificity of these antibodies extends to hRANK.
Biological effects of R12--31 and RANK--02 on human RANK
We used cell lines expressing hRANK or hRANK:Fas fusion protein to investigate the biological effects of the antibodies on hRANK. R12--31 again displayed agonist activity ( Fig. 2C, D) , the agonist activity of R12--31 is altogether roughly more than 10--fold less efficient on hRANK:Fas cells compared to mRANK:Fas cells, in line with its lower affinity for hRANK. RANK--02 exhibited weak agonist activity on hRANK:Fas cells at high concentrations (EC50 of 470 ng/ml) that however never induced complete apoptosis (Fig. 4B) . This apparent discrepancy with results obtained on mRANK:Fas cells might be explained by the intrinsic higher sensitivity of hRANK:Fas cells to apoptosis. Isotype controls had no effect at the highest dose tested for R12--31
and RANK--02 (Fig. 4C) . We next performed the NF--κB reporter assay in HEK 293--hRANK cells and observed agonist effects for both mAbs with RANK--02 displaying again weaker activity (Fig. 4D) .
These findings confirm that R12--31 is an agonist for RANK, across the species, and revealed a weak agonist effect of RANK--02 on hRANK. [18, 19] .
Whether the related dermal dendritic cells also express RANK is not known. After allowing cells to migrate from human skin into culture medium, they were harvested and labelled for different markers to identify three subsets (Fig.  6A) . The Langerhans cells (subset I) was clearly recognized by both RANK--02 and R12--31 mAbs (Fig.  6B) , the CD14 --dermal dendritic cells (subset II) expressed low levels of RANK, and the CD14 + population (subset III) was devoid of RANK (Fig. 6C, D) . Both mAbs are valid tools to detect RANK expression on primary cells, as the values of % positive Langerhans cells (Fig.  6E ) and the MFI (Fig.  6F) were not significantly different. The data show that migrated human Langerhans cells express the highest levels of RANK among human skin dendritic cells.
Assessment of antibody activity in vivo
To assess mAb activities in vivo, we determined the capacity of RANK--02 to inhibit recombinant RANKL to activate the release of the tartrate--resistant acid phosphatase isoform b (TRACP 5b) by osteoclasts [43, 44] . Mice received increasing doses of RANK--02 1 h before administration of 25 µg GST--RANKL (1mg/kg), and TRACP 5b was measured in the serum by ELISA 15 h later. RANKL resulted in a 30% increase of TRACP 5b, however RANK--02 did not significantly alter this level (Fig.  7A) . We had previously shown that the administration of GST--mRANKL induced the ectopic differentiation of cells of the villous small intestinal epithelium into microfold (M) cells [25] . We therefore tested whether R12--31 could induce the formation of villous M cells. To this end, mice were left untreated or received either R12--31 or GST--mRANKL for 5 days. Thin strips of intestinal tissue were then prepared for staining with rhodamine UEA--I that labels M cells. Small intestinal UEA--I + villous M cells were readily observed in mice treated with R12--31 or with recombinant RANKL, in contrast to untreated mice that showed only few UEA--I + cells (Fig.  7B,  C) . This shows that R12--31 exerts agonist activity in vivo.
Discussion
We estimated that a detailed characterization of two RANK--specific mAbs, one derived from a scFv selected against hRANK and one generated in the rat against mRANK [1, 2] , would be beneficial to their evaluation as therapeutic reagents and investigative tools. We found that both mAbs bound to mouse and human RANK--Fc in ELISA and surface plasmon resonance and recognized RANK--expressing cell lines or primary cells in flow cytometry. The mAbs recognized distinct epitopes on RANK and displayed differences in their biological activities and in their capacity to inhibit RANKL--RANK interaction. We showed that the agonist mAb R12--31 is functional in vivo.
RANK--02 and R12--31 recognized human and mouse RANK in ELISA, plasmon resonance and in flow cytometry. Cross--reactivity between RANK from both species can be expected because mouse and human RANK share 73% sequence identity [3] . R12--31, which was generated by immunization of rats with mRANK--transfected cells, had a high affinity for mRANK but a lower affinity for hRANK. Although
R12--31 comparatively stained mRANK--transfected cells better than hRANK--transfected ones, it was
good enough to label human Langerhans cells. RANK--02 was obtained using a phage display selection with the hRANK extracellular domain and had a high affinity for both human and mouse RANK. Thus, this mAb may be the reagent of choice to detect human cells expressing low levels of RANK, such as CD14 --dermal dendritic cells.
Biological activities of these antibodies were determined using cell lines stably expressing either RANK:Fas fusion proteins or full--length RANKs. Data showed that R12--31 was agonist on both human and mouse RANK, however, in line with its higher affinity, the activity was stronger on mRANK. A competitive ELISA further revealed that R12--31 most probably recognized a site distinct from that occupied by RANKL. This is compatible with a scenario upon which engagement of RANK by R12--31
induces conformational changes and/or aggregation of RANK that all in all mimic the action of the ligand. The biological activity of R12--31 was demonstrated in vivo by its ability to trigger the conversion of intestinal cells into M cells. The biological assays for RANK--02 yielded species--specific results: an antagonist activity was observed for mRANK and an agonist effect was seen for the human orthologue. However, its antagonist effect was weaker than that seen with anti--RANKL IK22--5
antibody, and the agonist activity may only have been detectable because of the high sensitivity of the cellular assays. In vivo, RANK--02 proved unable to inhibit recombinant RANKL--stimulated osteoclast activity. The competitive ELISA assay showed that RANK--02 competed at low concentrations with mouse and human RANKL for binding to hRANK. Thus, the capacity of RANK--02
to interfere with receptor--ligand interaction can explain its in vitro antagonist activity, while its agonist activity is likely triggered by its direct binding to RANK. EDAR is like RANK a TNF family member, and in a previous study characterizing a panel of anti--EDAR antibodies, it was found, using EDAR:Fas reporter cells, that several antibodies were agonist in this system while others were not.
What correlated with agonist activity in this experimental system was not the affinities of antibodies, but their ability to detach slowly once bound (small k off ) [42] . Interestingly, RANK--02 and R12--31 have the same affinity for mRANK but R12--31 has a lower k off rate. Differences in agonist activities between RANK--02 and R12--31 might also reflect binding epitopes that may be more or less favorable for generating an active conformation of the receptor. Indeed, we found that the mAbs recognized distinct epitopes on RANK. RANK--02 proved to be an excellent reagent for the detection of endogenous RANK on primary human skin Langerhans cells by FACS. A staining protocol with both antibodies would provide a strong guarantee of specificity because they recognize distinct epitopes, implying that if these antibodies cross--react with other antigens, these are unlikely to be shared. We confirm using primary human skin cells that Langerhans cells express high levels of RANK, whereas Langerhans cells have been shown to be more potent T cell activators than dermal dendritic cells [45] . Interestingly, RANK has also been implicated in the formation of regulatory T cells [12] , suggesting an implication of RANK in the regulation of immunity by Langerhans cells [46--48] . Hair follicles in their growth phase are a natural source of RANKL [31] , and this phase of the hair cycle is characterized by a reduced delayed--type hypersensitivity response [49] In conclusion, we have performed a detailed characterization of two anti--RANK mAbs with respect to affinity, specificity, activity and applications. These findings should help advance our understanding of RANK--RANKL--OPG biology and pave the way for their use in vitro and in vivo.
Figure legends relative to RANKL--induced NF--κB activation. RANKL was used at 0.1 µg/ml, IK22--5 at 10 µg/ml and RANK--02 at 50 µg/ml. For data panels C--F, statistical significance was calculated by one way Anova/Bonferroni using the PRISM software. Data is shown for 0.1 µg/ml RANKL, 25 µg/ml R12--31 and 50 µg/ml RANK--02. NT= non--treated cells.
Statistical significance was calculated by one way Anova/Bonferroni using the PRISM software. 
